BioSpace News Archive

Formerly Trask Orthodontics, Dr. Sepi Torkan continues the tradition of expert orthodontic care on Sand Point Way in the Laurelhurst neighborhood of Seattle.

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PhageBank™

Distinction Punctuates Neurological Spine Surgeon’s Storied Career as a Pioneer in High-Acuity, Minimally Invasive Surgery

Centene Corporation announced that it has commenced an underwritten public offering to sell $2,200,000,000 of senior notes due 2031, subject to market and other conditions.

Centene Corporation (NYSE: CNC) (" Centene " or the " Company ") announced today that it has commenced a cash tender offer (the " Tender Offer ") for any and all of its outstanding 4.75% Senior Notes due 2025 (the " 2025 Notes "). The Tender Offer is being made on the terms and subject to the conditions set forth in the Offer to Purcha

Doximity, the largest U.S. professional medical network, today announced the appointment of Tim Cabral to its board of directors and chair of the company’s audit committee.

During an unparalleled year, Burlington’s contribution supported LLS’s mission and furthered the LLS Children’s Initiative

Alveo Technologies, Inc. (Alveo) announced today that it has received its first regulatory approval with the CE (Conformité Européenne) Mark for its be.well™ COVID-19 Flex Test.

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPACTM) platform, announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.

Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19,